19th Annual Miami Breast Cancer Conference


	SECTION1: In view of the new data from the ATAC trial, should anastrozole now be used as adjuvant therapy for postmenopausal women with early invasive breast cancer?
	SECTION2: What is the optimal adjuvant endocrine therapy for premenopausal women with invasive breast cancer, including the role of ovarian ablation/suppression?
	SECTION 3: What are the current indications for sentinel node biopsy, and how should enhanced pathology (such as IHC) be used in clinical decision-making?
	SECTION 4: What is the optimal adjuvant chemotherapy for invasive breast cancer?
	SECTION 5: When should postmastectomy radiation therapy be utilized?
	SECTION 6: What is the optimal local and systemic therapy of local recurrence in the breast?
	SECTION 7: What is the optimal method and timing for breast reconstruction after mastectomy? What factors influence breast reconstruction?
	SECTION 8: What is the optimal local and systemic therapy of elderly women with breast cancer?
	SECTION 9: What is the optimal neoadjuvant endocrine therapy and when should it be used?
	SECTION 10: What is the optimal neoadjuvant chemotherapy regimen? When should it be used?
	SECTION 11: What is the optimal first-line chemotherapy for women with metastases, including the role of combination regimens such as docetaxel-capecitabine?
	SECTION 12: What is the optimal algorithm for assessment of tumor HER2 status?
	SECTION 13: When should chemotherapy be added to trastuzumab as first-line therapy for patients with HER2-positive metastatic disease and for how long should trastuzumab be continued?
	SECTION 14: What is the optimal sequencing of endocrine therapy in the metastatic setting and what is the role of fulvestrant?
	SECTION 15: What is the optimal approach for breast cancer risk assessment?
	SECTION 16: What is the optimal management of women at high risk for breast cancer, including the role of chemoprevention?
	SECTION 17: Is there a survival benefit to screening mammography and what is the optimal screening and diagnostic algorithm?
	SECTION 18: What is the role of ductal lavage in assessing breast cancer risk?
	SECTION 19: What is the optimal local and systemic therapy for DCIS? Do all DCIS patients need radiation therapy? What is the optimal endocrine therapy for DCIS?
	SECTION 20: What is the role of complementary or alternative medicine in the management of breast cancer?

	Breast Cancer Research Leaders with Edited Comments

Back | Top of Page

Home

Meeting Workbook:
    - About
    - Introduction
    - Editor's note
    - General Information
    - Program Agenda
    - Controversies in Breast Cancer

Education Supplement

Home · Contact us · Search our site